RCKT (Rocket Pharmaceuticals) Cyclically Adjusted FCF per Share: $-3.05 (As of Mar. 2026)


RCKT Rocket Pharmaceuticals Inc RCKT
25 GF Score
Price $3.84
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals Cyclically Adjusted FCF per Share?

Rocket Pharmaceuticals RCKT +9.25% 25 Cyclically Adjusted FCF per Share is $-3.05 as of Mar. 2026. GuruFocus rates RCKT with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Rocket Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.406. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-3.05 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-06), Rocket Pharmaceuticals's current stock price is $3.84. Rocket Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-3.05. Rocket Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Rocket Pharmaceuticals  (NAS:RCKT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Rocket Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Rocket Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -3.61 -3.40 -3.13

Rocket Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.35 -3.29 -3.26 -3.13 -3.05

RCKT vs TENX, DMAC, AVIR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Rocket Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


RCKT
25GF Score
Rocket Pharmaceuticals Inc RCKT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rocket Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.406/330.2130*330.2130
=-0.406

Current CPI (Mar. 2026) = 330.2130.

Rocket Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.236 241.018 -1.693
201609 -1.372 241.428 -1.877
201612 -1.674 241.432 -2.290
201703 -0.567 243.801 -0.768
201706 -0.405 244.955 -0.546
201709 -0.603 246.819 -0.807
201712 -2.319 246.524 -3.106
201803 -0.321 249.554 -0.425
201806 -0.249 251.989 -0.326
201809 -0.303 252.439 -0.396
201812 -0.520 251.233 -0.683
201903 -0.371 254.202 -0.482
201906 -0.500 256.143 -0.645
201909 -0.349 256.759 -0.449
201912 -0.566 256.974 -0.727
202003 -0.511 258.115 -0.654
202006 -0.479 257.797 -0.614
202009 -0.384 260.280 -0.487
202012 -0.498 260.474 -0.631
202103 -0.400 264.877 -0.499
202106 -0.635 271.696 -0.772
202109 -0.490 274.310 -0.590
202112 -0.512 278.802 -0.606
202203 -0.638 287.504 -0.733
202206 -0.640 296.311 -0.713
202209 -0.670 296.808 -0.745
202212 -0.776 296.797 -0.863
202303 -0.762 301.836 -0.834
202306 -0.684 305.109 -0.740
202309 -0.748 307.789 -0.802
202312 -0.364 306.746 -0.392
202403 -0.630 312.332 -0.666
202406 -0.595 314.175 -0.625
202409 -0.570 315.301 -0.597
202412 -0.484 315.605 -0.506
202503 -0.510 319.799 -0.527
202506 -0.441 322.561 -0.451
202509 -0.451 324.800 -0.459
202512 -0.312 324.054 -0.318
202603 -0.406 330.213 -0.406

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-3.05 mean?
Rocket Pharmaceuticals (RCKT) has a Cyclically Adjusted FCF per Share of $-3.05 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Rocket Pharmaceuticals and its competitors.
Is Rocket Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Rocket Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-3.05. Overall, Rocket Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' Cyclically Adjusted FCF per Share compare to TENX and DMAC?
Rocket Pharmaceuticals' Cyclically Adjusted FCF per Share of $-3.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current Cyclically Adjusted FCF per Share of $-3.05. The current Cyclically Adjusted FCF per Share is $-3.05. Rocket Pharmaceuticals' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current Cyclically Adjusted FCF per Share is $-3.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
25GF Score

Get the complete analysis for RCKT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price